
Aktiviere Job-Benachrichtigungen per E-Mail!
Erstelle in nur wenigen Minuten einen maßgeschneiderten Lebenslauf
Überzeuge Recruiter und verdiene mehr Geld. Mehr erfahren
A prominent research institute in Frankfurt am Main is seeking a Doctoral Researcher in Cancer Immunology to study the regulatory mechanisms controlling neutrophil function in cancer. The role involves investigating interactions between neutrophils and cancer cells using advanced genetic techniques. Applicants should hold a Master's degree in biomedical sciences and possess relevant lab skills. The position offers mentorship and a salary in accordance with public service agreements, available for 3 years with the possibility for extension.
Doctoral Researcher in Cancer Immunology
The Georg-Speyer-Haus in Frankfurt am Main, Institute for Tumor Biology and Experimental Therapy, is an academic non‑profit research institute supported by the Federal Ministry of Health and the Hessian Ministry of Science and Research, Arts and Culture. The institute is dedicated to basic and translational cancer research in the context of the tumor microenvironment and closely cooperates with the Goethe University Frankfurt and the Frankfurt University Hospital. It provides access to a broad variety of core facilities and an excellent scientific environment.
We are seeking a Doctoral Researcher (m/w/d) to join the lab of Máté Kiss at the Georg-Speyer-Haus Institute for Tumor Biology and Experimental Therapy, studying the regulatory mechanisms controlling neutrophil function in cancer.
Our lab will investigate the interactions between cancer and neutrophils, one of the most common immune cells in the human body which remain unexploited for cancer therapy. Tumors can reprogram neutrophils toward pro‑tumoral functions, whereas cancer immunotherapy can elicit a beneficial neutrophil response that supports tumor control. Our goal is to understand how specific signaling pathways and transcription factors drive these opposing neutrophil fates. We aim to identify regulatory circuits that establish tumor‑specific maladaptive neutrophil states and test whether disrupting key regulators can repolarize neutrophils to limit tumor progression. In parallel, we aim to elucidate how cancer immunotherapy primes an anti‑tumor neutrophil fate and identify regulators whose perturbation can enhance this beneficial neutrophil response.
We will use CRISPR‑based genetic perturbations in vitro and in vivo as well as pooled CRISPR‑screens in neutrophil progenitors to identify regulatory circuits that control neutrophil fate and function. To further study selected signaling pathways, we will employ mouse tumor models, gene editing in human neutrophil progenitors, transcriptomic, epigenomic and proteomic profiling, as well as flow cytometry and histological analyses.
Requirements
We offer
Interested?
Applications should be submitted electronically until January 15, 2026, to bewerbung@georg‑speyer‑haus.de as a single PDF containing a cover letter, CV (including list of publications if any), the names and contact details of at least two references, and academic transcripts from both the bachelor’s and master’s degrees.
Shortlisted candidates will be invited for an in‑person interview.
Our international working environment promotes equal opportunities for all staff regardless of gender, age, cultural background, nationality or impairments under criteria of scientific excellence. Applications from women are explicitly welcome. Disabled individuals will be preferred in case of equal qualification.
For Information about the Georg‑Speyer‑Haus please visit our website.